 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Personalis, Inc. (NASDAQ:PSNL  Get Free Report) was the target of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 899,600...

Short Interest in Personalis, Inc. (NASDAQ:PSNL) Grows By 20.9%

Personalis to issue 9.2M shares as Tempus joins hands for cancer test...

Personalis to issue 9.2M shares as Tempus joins hands for cancer test

Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Labs, Inc., a leader in artificial intelligence and precision medicine, today announced a strategic...

Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing

LPL Financial LLC increased its position in Personalis, Inc. (NASDAQ:PSNL  Free Report) by 9.4% in the second quarter, according to the company in its most recent filing with the Securities...

LPL Financial LLC Grows Position in Personalis, Inc. (NASDAQ:PSNL)

In trading on Monday, the ARK Genomic Revolution ETF is outperforming other ETFs, up about 3.3% on the day. Components of that ETF showing particular strength include shares of Personalis, up about...

Video: Monday's ETF Movers: ARKG, MOO

Myriad expands pharma service offering by introducing Personalis' ImmunoID NeXT platform to its pharmaceutical partners who use MyRisk Hereditary Cancer Test, BRACAnalysis CDx and/or MyChoice CDx...

Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2023 and provided recent business...

Personalis Reports Third Quarter 2023 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the launch of the Early Access Program for NeXT Personal Dx, a tumor-informed, whole...

Personalis Launches NeXT Personal Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2023 financial results on Tuesday, November 7, 2023. In...

Personalis to Announce Third Quarter 2023 Financial Results

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Personalis presents initial findings from work with RACERx lung cancer study

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Watchers	2,027
52-Wk Low	$0.8906
52-Wk High	$4.31

Market Cap	$75.02M
Volume (M)	664,239.00
52-Wk High	$4.31
52-Wk Low	$0.8906

Current Price	$1.47
Prev Close	$1.53
Open	$1.56
Dividend Yield	0.00%
50-Day Moving Average	$1.17
Beta	2.50
Avg. Volume	981,901.71
PE Ratio	-0.62

52-Week High	$4.31
52-Week Low	$0.8906
Market Capitalization	$75.02M
EPS	-$2.38
Price to Book	0.48
Revenue Per Employee	$176,761.90
Enterprise Value/EBITDA	0.15

PSNL Personalis Inc

About

Feed

News

Sentiment

Earnings

Fundamentals